Piper Sandler lowered the firm’s price target on Prothena (PRTA) to $81 from $110 and keeps an Overweight rating on the shares. The firm was disappointed to see Phase 3 AFFIRM-AL miss statistical significance on its primary and secondary endpoints despite initially being bullish on its potential. Consequently, Prothena will no longer pursue this asset, thus Piper removed birtamimab in AL amyloidosis from its model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena’s Strategic Shift and Promising Alzheimer’s Pipeline Drive Buy Rating
- Prothena price target lowered to $14 from $30 at H.C. Wainwright
- Prothena price target lowered to $29 from $78 at Citizens JMP
- Prothena price target lowered to $18 from $40 at Chardan
- Prothena downgraded to Hold from Buy at Jefferies